These results were obtained by measuring the bioluminescence emitted by the CXCR4+ luciferase+ AML cells at each affected site, findings that were validated observing a reduction of CD45+ AML cells in the liver and spleen at the end of treatment. This evidence concerns the gene PTPRC and acute myeloid leukemia.